Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Ana
- PDF / 491,767 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 41 Downloads / 186 Views
ORIGINAL RESEARCH
Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies Csaba Andra´s De´zsi
. Maria Glezer . Yuri Karpov
. Romualda Brzozowska-Villatte .
Csaba Farsang Received: August 12, 2020 / Accepted: October 8, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: Our objective was to determine the effectiveness of a perindopril/indapamide Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12325020-01527-3) contains supplementary material, which is available to authorized users. C. A. De´zsi (&) } r, University of Pe´cs, Division of Cardiology Gyo Pecs, Hungary e-mail: [email protected] C. A. De´zsi Department of Cardiology, Petz Alada´r County Teaching Hospital, Gyor, Hungary M. Glezer Department of Cardiology, Functional and Ultrasonic Diagnostics, Sechenov First Moscow State Medical University, Moscow, Russian Federation Y. Karpov National Medical Research Centre of Cardiology, 3rd Cherepkovskaya str., 15A, Moscow, Russian Federation e-mail: [email protected] R. Brzozowska-Villatte Global Medical Affairs Servier, Suresnes, France C. Farsang Semmelweis Medical University, Budapest, Hungary C. Farsang St. Imre University Teaching Hospital, Te´te´nyi u. 12-16, Budapest, 1115, Hungary e-mail: [email protected]
(Per/Ind) single-pill combination (SPC) in a broad range of patient profiles, including subgroups with varying hypertension severity, age and cardiovascular risk profiles. Methods: Patient data from four large prospective observational studies (FORTISSIMO, FORSAGE, PICASSO, ACES) were pooled. In each study, patients already treated for hypertension were switched to Per/Ind 10/2.5 mg SPC and systolic and diastolic blood pressure (SBP/DBP) measured at the 1-month (M1) and 3-month (M3) visits. Study endpoints included change in SBP and DBP from baseline to M1 and M3 and the percentage of patients achieving BP control (SBP/DBP \ 140/90 mmHg for patients without diabetes or \ 140/85 mmHg for patients with diabetes). Results: A total of 16,763 patients were enrolled and received Per/Ind (94% received the full dose of 10/2.5). Mean patient age was 61.4 years (36% were C 65 years old), 57% were women, and 16% had isolated systolic hypertension (ISH). Mean baseline office SBP/DBP was 162/94 mmHg, and mean duration of hypertension was 11 years. Cardiovascular risk factors and comorbid conditions were common in this population. Significant mean reductions in SBP (- 23 mmHg) and DBP (- 11 mmHg) were observed at M1 compared with baseline (P \ 0.001), which were maintained at M3 (- 30 mmHg and - 14 mmHg, respectively). At M3, BP control was achieved by 70% of patients (78% for ISH). In patients with
Adv Ther
SBP C 180 mmHg at baseline (grade III hypertension), the mean SBP/DBP decrease was - 51/- 20 mmHg and 53% achieved BP control. Per/Ind was well tolerated with an overall rate of adverse eve
Data Loading...
